Repligen Quarterly Cash Flow Statement
NASDAQ: RGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Repligen free cash flow
In the quarter ended Jun 30, 2026, Repligen generated $32.8 million of operating cash flow and spent $5.3 million on capital expenditures. That left free cash flow of $27.4 million, a free-cash-flow margin of 13.4% of revenue. Free cash flow was up 27.5% from the prior year's $21.5 million.
Summary generated from market data by MetaCap's automated system. Methodology
Repligen cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 5.01M | 8.33M | 13.29M | 14.91M | 14.87M | 5.83M | -33.87M | -654.00K | 5.71M | 3.30M | -16.45M | 16.92M |
| Net Income growth (YoY) | -66.31% | +42.93% | — | — | +160.21% | +76.88% | — | -103.86% | -71.13% | -78.51% | -133.76% | -58.12% |
| Depreciation & Amortization | 19.06M | 19.76M | 19.95M | 20.01M | 20.08M | 18.70M | 18.37M | 17.42M | 16.98M | 16.91M | 17.26M | 19.82M |
| Stock-Based Compensation | 8.01M | 8.32M | 7.98M | 8.97M | 8.38M | 7.27M | 6.36M | 23.05M | 9.88M | 8.78M | 6.46M | 6.37M |
| Change in Working Capital | -7.30M | -17.60M | -18.61M | 13.83M | -6.60M | -20.83M | 43.39M | 6.54M | 924.00K | 12.47M | -6.58M | 36.10M |
| Operating Cash Flow | 32.77M | 28.30M | 25.70M | 48.10M | 28.61M | 15.01M | 39.18M | 49.32M | 42.19M | 44.71M | 29.07M | 39.23M |
| Capital Expenditures | -5.33M | -4.71M | -8.15M | -4.70M | -7.10M | -3.56M | -5.54M | -6.98M | -4.81M | -8.35M | -11.09M | -8.39M |
| Investing Cash Flow | -2.09M | -3.99M | -208.74M | -7.78M | -7.84M | -74.11M | -64.76M | -5.86M | -7.40M | -8.36M | -169.91M | -8.77M |
| Financing Cash Flow | -6.20M | -5.54M | 195.00K | -239.00K | -10.13M | -5.03M | 1.45M | -69.60M | -5.77M | -8.97M | 268.13M | -778.00K |
| Net Change in Cash | 24.17M | 18.62M | -182.73M | 39.89M | 11.63M | -60.13M | -26.61M | -25.18M | 28.53M | 29.29M | 120.54M | 27.12M |
| Free Cash Flow | 27.43M | 23.59M | 17.55M | 43.40M | 21.51M | 11.44M | 33.64M | 42.34M | 37.38M | 36.36M | 17.98M | 30.84M |
This table shows 12 quarterly periods of Repligen's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow RGEN's reporting calendar. What is a cash flow statement?